Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 Replication

被引：9

作者：

Skerlj, Renato ^{[1
]}

Bridger, Gary ^{[2
]}

Zhou, Yuanxi ^{[2
]}

Bourque, Elyse ^{[1
]}

McEachern, Ernest ^{[2
]}

Danthi, Sanjay ^{[1
]}

Langille, Jonathan ^{[2
]}

Harwig, Curtis ^{[2
]}

Veale, Duane ^{[2
]}

Carpenter, Bryon ^{[2
]}

Ba, Tuya ^{[2
]}

Bey, Michael ^{[2
]}

Baird, Ian ^{[2
]}

Wilson, Trevor ^{[2
]}

Metz, Markus ^{[1
]}

MacFarland, Ron ^{[2
]}

Mosi, Renee ^{[2
]}

Bodart, Veronique ^{[2
]}

Wong, Rebecca ^{[2
]}

Fricker, Simon ^{[1
]}

Huskens, Dana ^{[3
]}

Schols, Dominique ^{[3
]}

机构：

[1] Genzyme Corp, Waltham, MA 02451 USA

[2] Anormed Inc, Langley, BC V2Y 1N5, Canada

[3] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2012年 / 3卷 / 03期

基金：

英国医学研究理事会;

关键词：

HIV-1; hERG; CCR5; chemokine receptor; LONG-QT SYNDROME; MARAVIROC; GO;

D O I：

10.1021/ml2002604

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of CCR5 antagonists representing the thiophene-3-yl-methyl ureas were designed that met the pharmacological criteria for HIV-1 inhibition and mitigated a human ether-a-go-go related gene (hERG) inhibition liability. Reducing lipophilicity was the main design criteria used to identify compounds that did not inhibit the hERG channel, but subtle structural modifications were also important. Interestingly, within this series, compounds with low hERG inhibition prolonged the action potential duration (APD) in dog Purkinje fibers, suggesting a mixed effect on cardiac ion channels.

引用

页码：216 / 221

页数：6

共 50 条

[21] Maraviroc - a CCR5 antagonist for the treatment of HIV-1 infection
Van Der Ryst, Elna
FRONTIERS IN IMMUNOLOGY, 2015, 6
[22] CCR5 genotype and resistance to vertical transmission of HIV-1
Philpott, S
Burger, H
Charbonneau, T
Grimson, R
Vermund, SH
Visosky, A
Nachman, S
Kovacs, A
Tropper, P
Frey, H
Weiser, B
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 21 (03): : 189 - 193
[23] Owl monkey CCR5 reveals synergism between CD4 and CCR5 in HIV-1 entry
Nahabedian, John
Sharma, Amit
Kaczmarek, Maryska E.
Wilkerson, Greg K.
Sawyer, Sara L.
Overbaugh, Julie
VIROLOGY, 2017, 512 : 180 - 186
[24] Coreceptor choice and T cell depletion by R5, X4, and R5X4 HIV-1 variants in CCR5-deficient (CCR5Δ32) and normal human lymphoid tissue
Malkevitch, N
McDermott, DH
Yi, YJ
Grivel, JC
Schols, D
De Clercq, E
Murphy, PM
Glushakova, S
Collman, RG
Margolis, L
VIROLOGY, 2001, 281 (02) : 239 - 247
[25] The chemokine receptor CCR5: multi-faceted hook for HIV-1
Natacha Faivre
Christel Verollet
Fabrice Dumas
Retrovirology, 21
[26] The chemokine receptor CCR5: multi-faceted hook for HIV-1
Faivre, Natacha
Verollet, Christel
Dumas, Fabrice
RETROVIROLOGY, 2024, 21 (01)
[27] A piece de resistance: how HIV-1 escapes small molecule CCR5 inhibitors
Moore, John P.
Kuritzkes, Daniel R.
CURRENT OPINION IN HIV AND AIDS, 2009, 4 (02) : 118 - 124
[28] Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc
Latinovic, Olga
Kuruppu, Janaki
Davis, Charles
Le, Nhut
Heredia, Alonso
CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1497 - 1510
[29] HIV-1与CCR5受体关系研究概况
宋娜丽
云南中医中药杂志, 2012, 33 (10) : 64 - 66
[30] Enhanced Replication of R5 HIV-1 Isolates in vitro by a Small-Molecule Reagent Targeting HIV-1 Protease
Wardle, Nick J.
Hudson, Harry R.
Matthews, Ray W.
Nunn, Christine M.
Vella, Cherelyn
Bligh, S. W. Annie
CHEMMEDCHEM, 2013, 8 (05) : 719 - 721

← 1 2 3 4 5 →